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Abstract: Metalloaminopeptidases (mAPs) are enzymes that are involved in 
HIV infectivity, tumor growth and metastasis, angiogenesis, and bacterial 
infection. Investigation of structure-function relationships in mAPs is a 
prerequisite to rational design of anti-mAP chemotherapeutics. The most 
intensively studied member of the biomedically important dinuclear mAPs is 
the prototypical secreted Vibrio proteolyticus di-zinc aminopeptidase (VpAP). 
The wild-type enzyme is readily purified from the supernatant of cultures of 
V. proteolyticus, but recombinant variants require expression in Escherichia 
coli. A greatly improved system for the purification of recombinant VpAP is 
described. A VpAP-(His)6 polypeptide, containing an N-terminal propeptide, 
and a C-terminal (His)6 adduct, was purified by metal ion affinity 
chromatography from the supernatant of cultures of E. coli. This single step 
replaced the sequence of (NH4)2SO4 fractionation, and anion exchange and 
hydrophobic interaction chromatographic separations of earlier methods. 
Traditionally, recombinant VpAP proenzyme has been treated with proteinase 
K and with heat (70 °C), to remove the N- and C-terminal regions, and yield 
the mature active enzyme. This method is unsuitable for VpAP variants that 
are unstable towards these treatments. In the new method, the hitherto 
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noted, but not fully appreciated, ability of VpAP to autocatalyze the hydrolysis 
of the N-terminal propeptide and C-terminal regions was exploited; extensive 
dialysis of the highly purified VpAP-(His)6 full-length polypeptide yielded the 
mature active protein without recourse to proteinase K or heat treatment. 
Purification of variants that have previously defied isolation as mature forms 
of the protein was thus carried out. 
Introductory Statement 
Metalloaminopeptidases (mAPs) are key players in many 
biological processes, including cellular targeting of proteins [1, 2], 
protein degradation [1, 3, 4], aging [5-10], tissue repair [11-15], 
cataract formation [16-22], HIV infectivity [23-26], angiogenesis [27-
31], and carcinogenesis [27, 32-34]. A biomedically important family 
of mAPs is that of the dinuclear mAPs, also known as “cocatalytic” 
mAPs [35]. The dinuclear mAPs hydrolyze the N-terminal amino acid 
from peptides and proteins, with varying degrees of substrate 
specificity, and are characterized by an active site that contains two 
transition ions, usually Zn(II), separated by about 0.35 nm (3.5 Å) in a 
dinuclear active site. The most intensively studied and well 
characterized of these enzymes is the 32kD secreted di-zinc leucine 
aminopeptidase, VpAP, from Vibrio proteolyticus (formerly Aeromonas 
proteolytica) [36-40]. It appears that one of the metal ions in VpAP 
and related mAPs is involved in nucleophile activation, and is essential 
for catalysis, whereas the other is involved in substrate activation and 
stabilization of the transition state [36, 39, 41]; the non-essential 
metal ion may thus be key to substrate specificity, though conclusive 
evidence is lacking. Other dinuclear mAPs that have been studied 
include the angiogenesis target methionyl aminopeptidase, and the 
secreted aminopeptidases that are virulence factors in the 
pathogenicity of certain species of Clostridium, Streptomyces, Vibrio 
and Aeromonas [42-48]. VpAP itself exhibits a very high degree of 
structural homology with the protease domain of the prostate-specific 
membrane antigen (PSMA) [49]. PSMA is highly expressed in prostate 
cancer cells [50], but its role in prostate cancer is currently unknown. 
Some potent inhibitors of VpAP and its homologs, including bestatin 
(ubenimex), ovalicin, and fumagillin, have also been shown to exhibit 
in vivo activity against tumor growth, angiogenesis, and HIV infectivity 
[8, 24, 51-59]. Wild-type VpAP is readily available in large quantities 
from V. proteolyticus, and it is an excellent model protein with which 
to explore the structure-function relationships of mAPs: studies on 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Protein Expression and Purification, Vol. 66, No. 1 (July 2009): pg. 91-101. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
3 
 
VpAP have provided information that may lead to the design of more 
effective and specific chemotherapeutic agents [35, 39-41, 60]. 
However, recent work on VpAP and VpAP homologs has shown that 
site-directed recombinant variants can provide important mechanistic 
information that is unavailable with the native proteins [61-64]. A 
need exists, therefore, for an efficient expression system and 
purification protocol for recombinant VpAP that can provide sufficient 
quantity of high-purity material for physicochemical, structural, and 
spectroscopic study of site-directed variants of VpAP. 
VpAP has been isolated from cultures of V. proteolyticus since 
the mid-1960s. Investigation of the proteolytic activity associated with 
V. proteolyticus [65] led to the identification and isolation of VpAP by 
Prescott and Wilkes [66]. Subsequent refinements of the purification 
procedure [67, 68] resulted in a protocol that yielded VpAP 
preparations that were sufficiently homogenous for crystallization. The 
purification of VpAP is complicated by the fact that the 32 kDa mature 
active protein is the product of substantial processing of a 54 kDa 
translated polypeptide, VpAP*, coded for by the native ORF [69, 70]. 
The 54 kDa VpAP* polypeptide consists of a 21 amino acid signal 
peptide, an 85 amino acid N-terminal propeptide, a 299 amino acid 
mature region, and a 99 amino acid C-terminal propeptide (Figure 1). 
The signal peptide is required for secretion, the N-terminal propeptide 
is required for folding but its presence inhibits catalytic activity, and 
the C-terminal propeptide is of undetermined function but appears to 
be species-specific [71, 72]. VpAP* is processed to the final 32 kDa 
mature protein only after secretion and during purification; roles in the 
processing of VpAP* have been proposed for VpAP* itself (and VpAP) 
in autoprocessing, for a co-expressed neutral protease, and for a heat-
treatment step that has been traditionally employed [73-75]. An 
additional problem in the purification of VpAP for spectroscopic studies 
is the presence of two low Mr (< 2kD) brown pigments, one of which 
contains spectroscopically active Fe(III), that appear to be closely 
associated with VpAP; any successful protocol must separate these 
pigments from VpAP [76]. 
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Figure 1. Linear representations of various VpAP species. VpAP* is the native 
polypeptide secreted by V. proteolyticus. ΔspΔCVpAP* is the polypeptide secreted by 
E. coli expressing a construct of VpAP lacking the C-terminal polypeptide. 
ΔspΔCVpAP*(His)6 is the polypeptide secreted by E. coli containing a plasmid that 
included the new construct described herein. N-terminal processing of 
ΔspΔCVpAP*(His)6 yields ΔNΔCVpAP*(His)6, and subsequent C-terminal processing 
yields the mature VpAP polypeptide. The experimentally observed N-terminal 
sequences are shown. The N-terminal sequence of natively expressed mature VpAP is 
MPPI. Proteinase K treatment of recombinant VpAP* yielded a final N-terminal 
sequence of ASFVMPPI, whereas autoprocessing resulted in an N-terminal sequence of 
TLASFVMPPI. “N-pro-p.” and “C-pro-p.” denote the N- and C-terminal propeptides, 
respectively, and “s.p.” denotes a signal peptide. 
The commonly and successfully used protocol for the purification 
of VpAP from V. proteolyticus involves (i) rapid separation of the 
supernatant from V. proteolyticus cells; (ii) (NH4)2SO4 fractionation of 
the supernatant; (iii) heat treatment (70 °C for 5 – 7 h), followed by 
dialysis and clarification by centrifugation and filtration (0.22 μm); (iv) 
one or two hydrophobic interaction chromatographic fractionations 
(octyl-Sepharose); and (v) anion-exchange chromatography (Q-
Sepharose). A highly detailed investigation into the requirements for 
the isolation of VpAP heterologously expressed in E. coli has been 
described by Bzymek, Holz and coworkers [71], and the resulting 
protocol has yielded both recombinant wild-type and site-directed 
variant forms of VpAP for subsequent crystallographic and 
physicochemical studies [38, 61-63, 71]. As suggested by earlier work 
[72, 77-79], it was found that VpAP was best expressed as a 52 kDa 
proenzyme (ΔspVpAP*; lacking the first 23 amino acids); the use of an 
appropriate leader sequence (e.g. the pelB sequence of pET26b(+)) 
results in secretion of the proenzyme, which can be purified from the 
supernatant. Essentially the same purification procedure as for the 
native enzyme from V. proteolyticus was adopted, except for an 
additional incubation with proteinase K (PK), which appears to mimic 
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the effects of V. proteolyticus neutral protease and removes the N-
terminal propeptide, prior to heat treatment. 
In the course of our own studies, we have followed the earlier 
procedure [71] for the purification of recombinant wild-type and 
variant VpAP and have successfully isolated VpAP with amino acid 
substitutions in the active site pocket and in an adjacent hydrophobic 
pocket [39]. However, we have also encountered problems, including 
(i) irreproducible, and generally low, yields of VpAP; (ii) 
unpredictability of the effects of PK on variant forms of VpAP*; and 
(iii) the inability to isolate some site-directed variants as the mature 
proteins, notably variants with substitutions of Asp99. In the present 
work, we describe a rapid purification scheme for heterologously 
expressed VpAP that reproducibly yields 10 mg of pure wild-type VpAP 
per liter of E. coli culture. In addition, we describe the expression and 
purification of the D99A, D99H, and D99M variant forms of VpAP, that 
had hitherto defied isolation as mature proteins. The advantages of the 
new method are discussed. 
Materials and Methods 
General chemicals and reagents 
Restriction enzymes, T4 DNA ligase, and Antarctic phosphatase 
were purchased from New England Biolabs (Ipswich, MA). A dNTP 
cocktail and Pfu Turbo polymerase were purchased from Stratagene 
(La Jolla, CA). BL21 Star DE3 One Shot Chemically Competent E. coli 
cells were purchased from Invitrogen (Carlsbad, CA). LB medium and 
kanamycin were purchased from Fisher Scientific (Fair Lawn, NJ). IPTG 
was obtained from Anatrace Incorporated (Maumee, OH), aliquoted 
into 1 ml volumes of 1 M concentration, and stored at −20 °C until 
use. Pre-cast PAGE gels were purchased from BioRad Laboratories 
(Hercules, CA). Agarose bead-linked proteinase K from Tritirachium 
album was purchased from Sigma-Aldrich (St. Louis, MO). All other 
general chemicals (ACS grade) and buffer salts (Biotech or 
electrophoresis grade) were obtained from Sigma-Aldrich (St. Louis, 
MO). Deionized water was additionally filtered for organic and metal 
ion contaminants using a Milli-Q system (Millipore, Molsheim, France) 
and exhibited a resistance of > 18 MΩ. 
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Plasmids 
cDNA was amplified by PCR from the plasmid pVSNMC [72], 
obtained from the Applied Enzymology Laboratory of the National Food 
Research Institute (Ibaraki, Japan), using the forward and reverse 
primers 5′-GGCTTCCATGGAAGACAAAGTGTGGATCTCA-3′ (forward; 
NcoI site underlined), and 5′-GCGCGCCTCGAGCTGATTGCC-3′ 
(reverse; XhoI site underlined). The PCR product was then inserted 
between the NcoI and XhoI sites of pET26b(+) (Invitrogen, Carlsbad, 
CA). The reverse primer lacked the VpAP native stop codon, thus 
transcription continued through the (His)6-coding sequence 
immediately downstream of the XhoI site in pET26b(+), and was 
stopped immediately after (His)6. The resulting construct, pAPMH, was 
used to express a wild-type polypeptide (ΔspΔCVpAP*(His)6) 
containing the N-terminal propeptide, the mature VpAP polypeptide, 
and a C-terminal (His)6 construct, but lacking the signal sequence and 
the C-terminal propeptide. pAPMH was also used as the template to 
generate VpAP site-directed variants. 
Recombinant DNA for the D99A, D99M, and D99H variants of VpAP 
was generated using the following primers (mutations underlined): 
D99A forward, 5′-GGTGGTCACCTTGCTTCGACCATTGGTTCAC-3′; 
D99A reverse, 5′-GAACCAATGGTCGAAGCAAGGTGACCACC-3′; 
D99M forward, 5′-GGTGGTCACCTTATGTCGACCATTGGTTCACAC-3′; 
D99M reverse, 5′-GTGTGAACCAATGGTCGACATAAGGTGACCACC-3′; 
D99H forward, 5′-GGTGGTCACCTTCATTCGACCATTGGTTCACAC-3′; 
D99H reverse, 5′-GGTGGTCACCTTCATTCGACCATTGGTTCACAC-3′. 
A six-step PCR protocol was employed with the following parameters: 
step 1, 95 °C for 1 min; step 2, 95 °C for 30 s; step 3, primer Tm − 
10 °C, 1 min; step 4, 68 °C for 8 min; step 5, 18 cycles of steps 2 – 4; 
step 6, 68 °C for 10 min. 
All constructs were fully sequenced (Applied Biosystems ABI 
PRISM 3100 analyzer, Protein and Nucleic Acid Facility, Medical College 
of Wisconsin, Milwaukee, WI) and found to contain no mutations 
except for those intended. Sequence-verified constructs were used to 
transform BL21 Star (DE3) One Shot Chemically Competent E. coli 
cells (F- ompT hsdSB (rB-mB-) gal dcm rne131 (DE3)), using the 
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transformation protocol provided by the manufacturer (Invitrogen, 
Carlsbad, CA). Frozen stocks were prepared by adding 1 ml bacterial 
culture (OD600 nm ≈ 0.6) to 1 ml 30% glycerol (in water), snap frozen 
in liquid nitrogen, and stored at −80 °C. 
Expression of VpAP 
Starter cultures were prepared by inoculation of 20 ml LB, 
containing 30 μg/ml kanamycin, with a scraping from frozen stock 
cultures, followed by agitation at 250 rpm, 37 °C, in a 50 ml conical 
tube, until the OD600 nm reached 1.0. Cultures for VpAP expression were 
prepared by adding 2.5 ml of starter culture to a 1 L flask containing 
250 ml LB (30 μg/ml kanamycin). Flasks were agitated in an orbital 
shaker at 250 rpm, 37 °C until OD600 nm = 0.6. IPTG was added (to a 
final concentration of 1 mM), and flasks were further agitated for 18 h, 
250 rpm, 30 °C. 
Assay of VpAP 
Steady state VpAP activity was estimated from 
spectrophotometric determination of the rate of formation of the 
product, p-nitroaniline (PNA), of hydrolysis of L-leucine-p-nitroaniline 
(LPNA; Sigma, St. Louis, MO), at 405 nm, 25 °C. The assay mixture 
contained 1.0 mM LPNA in 10 mM Tricine buffer, pH 8.0 [67, 80] and a 
differential extinction coefficient Δε405 nm = 10,800 M-1 cm-1 was 
employed [81]. A “Unit” of activity was defined as a rate of hydrolysis 
of 1 μmol LPNA min-1 under these conditions. Apparent kinetic 
parameters K′m and k′cat were estimated by collecting the entire 
progress curve, with initial [LPNA] = 0.1 mM, and fitting the part of 
the curve that exhibited a linear relationship between t-1[ln([S0]/[St])] 
and t-1[S0 − St] [39, 82]. This approach indicated that the steady state 
assay routinely underestimated Vmax by a factor of 1.3, likely because 
of weak substrate inhibition, but steady state values were determined 
for wild-type VpAP for comparison to other studies. Quantities of 
ΔspΔCVpAP*(His)6 were estimated spectrophotometrically, taking ε280 
nm = 58,110 M-1 cm-1, and purified mature VpAP protein was estimated 
taking ε280 nm = 43,950 M-1 cm-1 [76, 83-85]. SDS-PAGE analysis was 
carried out on precast 4 - 15 % polyacrylamide/Tris-HCl gels (BioRad 
“Ready Gels”). Samples of VpAP were generally loaded directly onto 
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SDS-PAGE gels without pretreatment. Occasionally, samples were 
heated for 5 min at 95 °C in the presence of either 33 mM 
dithiothreitol, 66 mM β-mercaptoethanol, or both, prior to SDS-PAGE 
analysis. These pretreatments were found to diminish the intensities of 
bands showing anomalously high apparent Mr, but did not affect the 
number or the positions of the bands. SDS-PAGE analyses presented 
herein were carried out on samples that had not been pretreated, 
except where explicitly stated in the figure legend (i.e. only Figure 4). 
 
Figure 4: Time dependence of incubation with proteinase K on the apparent Mr of 
VpAP. Lane 1, Recombinant VpAP prior to proteinase K exposure; Lane 2, after further 
incubation (90 min) with proteinase K; Lane 3, Mr markers. (β-mercaptoethanol and 
dithiothreitol were employed in the sample buffers). 
  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Protein Expression and Purification, Vol. 66, No. 1 (July 2009): pg. 91-101. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
9 
 
Purification of wild-type VpAP 
Step A: Cultures were clarified by centrifugation (5200 × g, 10 min, 
4 °C), and 1 L supernatant was applied (3.0 ml/min, 4 °C) to 15 ml 
TALON Superflow Metal Affinity Resin (Clontech, Mountain View, CA). 
The resin was washed with 75 ml of 50 mM HEPES buffer, pH 7.5, at 
1.0 ml/min. HEPES buffer (50 mM, pH 7.5), containing imidazole (20 
mM), was applied (3.0 ml/min) to effect protein elution. Fractions (6 
ml) were assayed for activity and protein content. In order to speed 
future identification of fractions containing site-directed variants of 
VpAP that may show no detectable activity, the retention volumes for 
the fractions of wild-type VpAP with highest specific activity were 
characterized from the commencement of application of imidazole. 
Fractions containing protein and expressing VpAP activity were 
combined and dialyzed at 4 °C against 50 mM HEPES buffer, pH 7.5, 
to dilute imidazole to a final concentration of < 1 nM. 
Step B: The dialysate from Step A was agitated (250 rpm, 37 °C) with 
≈ 5 mg (≈ 0.025 units; ≈ 1 μg protein equivalent) PK agarose beads. 
Aliquots were periodically assayed for VpAP activity toward LPNA. 
When the activity toward LPNA ceased to increase upon further 
incubation with PK (generally ≈ 40 min), the VpAP-containing 
suspension was filtered to remove the PK beads (0.22 μm, Millipore 
mixed cellulose esters [MCE] syringe filter). 
Step C: The solution from Step B was immediately incubated at 70 °C 
in a water bath, either until the activity began to decrease, or else for 
1 h. The suspension was cooled on ice, filtered (0.22 μm), and 
dialyzed (50 mM HEPES, pH 7.5, 4 °C). 
Step D: The solution from Step C was applied (2.0 ml/min, 4 °C) to a 
15 ml TALON Co(II)-affinity resin column. HEPES buffer (50 mM, pH 
7.5) was applied, and eluate fractions that contained the highest 
specific activity toward LPNA were pooled and concentrated by 
ultrafiltration (Amicon PM10). As in Step A, retention volumes were 
characterized. 
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Purification of VpAP D99-substituted variants D99A, 
D99H and D99M 
Step A was carried out as for wild-type VpAP. Because the 
activities of the D99-substituted variants were extremely low at this 
stage, fractions were collected using the retention volumes 
characterized for wild-type. Protein content was estimated from A280 
nm. Steps B and C, however, were replaced by Step E, which entailed 
extended (7 – 14 d) dialysis against HEPES buffer (50 mM, pH 7.5) at 
4 °C. Self-processing of VpAP D99-substituted variants was monitored 
by SDS-PAGE on 4 – 20 % polyacrylamide gradient gels. When SDS-
PAGE and N-terminal amino acid sequencing indicated complete 
processing, the dialysate was filtered (0.22 μm), and further processed 
as described for Step D for wild-type VpAP. The previously 
characterized retention volumes for wild-type VpAP were used as an 
aid to identifying fractions containing VpAP D99-substituted variants. 
N-terminal amino acid sequencing 
Proteins were separated on SDS-PAGE gels, transferred to 
polyvinylidene fluoride membranes, excised, and N-terminal 
sequenced by Edman degradation using a Beckman Porton LF3000G 
sequencer with in-line Applied Biosystems PTH analyzer, at the Protein 
and Nucleic Acid Core Facility at the Medical College of Wisconsin. 
Circular dichroism spectropolarimetry 
Circular dichroism spectra were recorded at 25 °C using a 
JASCO J-710 spectropolarimeter equipped with a 1 mm path-length 
quartz cell. Samples for spectropolarimetry were equilibrated with 5 
mM phosphate buffer, pH 7.5, by dialysis. 
Crystallization of heterologously expressed VpAP 
VpAP was crystallized from a hanging drop. VpAP (0.5 mM) in 
10 mM Tris buffer, pH 8.0, containing 10 mM KSCN and 400 mM NaCl 
was equilibrated with 100 mM Tris buffer, pH 8.0, containing 100 mM 
KSCN and 4.5 M NaCl, at 19 °C. 
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X-ray diffraction 
Diffraction data were collected on a single crystal of 
heterologously expressed wild-type VpAP, with Paratone-N (Hampton) 
as a cryoprotectant, at −160 °C on a Rigaku R-AXIS IV++ 
diffractometer using Crystal Clear software [86]. An oscillation step 
size of 1.0° was used to collect 3 min exposures. Data were processed 
and unit cell parameters determined with HKL2000 [87]. Phases were 
derived from a structure previously solved in this laboratory (accession 
code 2IQ6 [88]) and used to solve the structure by molecular 
replacement using Phaser [89]. Model building was performed with the 
graphic program COOT [90]. The structure was manually inspected 
with electron density maps and with 2Fobs − Fcalc and Fobs − Fcalc 
coefficients. Structures were refined using iterative cycles of energy 
minimization using REFMAC5 [91] in the CCP4 program suite [92], 
alternating with manual map-fitting and model rebuilding. Progress of 
the refinement was confirmed by the steady decrease in both the 
Rcrystal and Rfree values. Procheck was used to check Ramachandran (φ, 
ψ) values [93]. 
Results 
Expression and purification of wild-type VpAP 
10 L of E. coli culture, OD600 nm = 2.3, yielded 20 g wet weight of 
cells, which were discarded. Up to 10 mg of wild-type VpAP, with a 
steady state ([LPNA] ≈ 1 mM) specific activity of 120 Units/mg at 
25 °C, was purified from the supernatant. The purification of wild-type 
VpAP is summarized in Table 1. Kinetic analysis indicated apparent 
Michaelis-Menten parameters k′cat = 82 ± 2 s-1, and K′m = 18 ± 1 μM. 
Table 1: Purification of wild-type VpAP 
Purification step Volume 
(ml) 
Total protein 
(mg) 
Activity 
(Units) 
Specific activity 
(Units/mg) 
Supernatant clarification 10,000 120,000a 320 0.003a 
Step A 20 80 480 6 
Steps B and C 20 68 7480 110 
Step D 40 60 7200 120 
aVpAP was purified from the supernatant of bacterial cultures grown in LB medium, 
that originally contained about 12 g/L of a mixture of peptides, peptones and proteins. 
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Step A: VpAP-containing fractions that eluted during Co(II)-affinity 
chromatography upon the application of imidazole were characterized 
by three bands on SDS-PAGE, at apparent Mr ≈ 57 kDa, ≈ 42 kDa, and 
≈ 32 kDa (bands A, B, and C of Figure 2). The relative intensities of 
the bands appeared to be the same for each fraction. The origin of the 
the “57 kDa” band, A, is unclear, as the cDNA coded for the 42kD 
ΔspΔCVpAP*(His)6 polypeptide, but that material evidently bound the 
Co(II) affinity resin with an affinity comparable to that for the material 
responsible for the other two bands. N-terminal amino acid sequencing 
of the other two bands, B and C, indicated the same N-terminal 
sequence of EDKVWI for each, corresponding to the N-terminal region 
of the 85 amino acid N-terminal propeptide, and these bands were 
only observed in fractions that eluted upon the application of 
imidazole, so contain the (His)6 adduct. Despite the apparent Mrs from 
SDS-PAGE, then, both bands B and C must be due to 
ΔspΔCVpAP*(His)6. The specific activity of the material following Step 
A was ≈ 6 Units/mg, consistent with the retention of the inhibitory N-
terminal propeptide in > 95 % of the polypeptide molecules. 
 
Figure 2: SDS-PAGE analysis of Co(II)-affinity resin chromatographic fractionation of 
wild-type VpAP-induced E. coli culture supernatant. Lane 1, Mr markers (pre-stained 
Novex Sharp, Invitrogen; note that the band between 40 kDa and 60 kDa is 50 kDa); 
Lane 2, Flow-through during application of supernatant; Lane 3, Flow-through during 
washing with HEPES buffer; Lanes 4 - 6, Eluate upon application of imidazole-
containing buffer. 
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The anomalous behavior of VpAP on SDS-PAGE is worthy of 
comment. The apparent Mr of proteins from SDS-PAGE can be very 
sensitive to even very minor differences in physicochemical properties 
of polypeptides in some cases [94, 95]. Here, the origin of the 
anomalous behavior on SDS-PAGE is unknown, but may be related to 
the presence of cysteines with the potential to form disulfide bonds. 
Mature VpAP contains only two cysteines, Cys223 and Cys227, that 
form a disulfide bond. Larger recombinant constructs, however, 
contain up to three additional cysteines; one is in the N-terminal 
propeptide, and two reside in the C-terminal propeptide. The 
ΔspΔCVpAP*(His)6 construct contains three cysteines. It is highly 
likely, given the thermostability of VpAP, that the Cys223-Cys227 
disulfide bond is very stable and that neither of these cysteines forms 
a disulfide bond with the third cysteine in any significant fraction of the 
sample. It is, however, possible that the cysteine that resides on the 
N-terminal propeptide engages in intermolecular disulfide bond 
formation. The presence of the N-terminal propeptide inhibits activity 
and so likely is adjacent to the active site in the folded polypeptide; 
given the extensive secondary structure and hydrophobic surface of 
VpAP, dimers thus formed would likely be of high stability and possibly 
partially resistant to SDS, leading to incomplete unfolding and the 
presence of multiple bands. In SDS-PAGE analysis of VpAP after Step 
A, pretreatment of samples by heating with β-mercaptoethanol and/or 
dithiothreitol was found to diminish the intensity of the “57 kDa” and 
“42 kDa” bands somewhat, but not completely. The thermostability of 
VpAP (see Step C) may be related to this phenomenon. An additional 
factor that may contribute to the anomalous behavior of unprocessed 
and partially processed VpAP on SDS-PAGE is the presence of regions 
of high hydrophobicity in both the mature VpAP sequence [96], and, 
particularly, in the N-terminal propeptide. 
Steps B and C: SDS-PAGE comparison of the material from Step A 
(Lane 2, Figure 3) with those from Steps B (Lane 3, Figure 3) and C 
(Lane 4, Figure 3) shows clear differences. Treatment with PK yielded 
a dominant species with an apparent Mr of 32 kDa, and some minor 
species of higher and lower apparent Mr. In contrast to results from 
Step A, N-terminal sequencing of the major band from Step B returned 
ASFVMP, indicating loss of the N-terminal propeptide [71]; the N-
terminal region of mature natively-expressed VpAP begins MPPI, and is 
preceded in this recombinant protein by ASFV from the C-terminal 
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sequence of the N-terminal propeptide. The specific activity of ≈ 110 
Units/mg was consistent with removal of the N-terminal propeptide. 
More extensive incubation with PK (> 1 h) yielded a species with an 
apparent Mr of 28 kDa, with no change in catalytic activity (Figure 4). 
Two bands with apparent Mr of 28 and 32 kDa are routinely observed 
with preparations of natively-expressed VpAP, and mass spectrometry 
has indicated that the two bands correspond to species with almost 
indistinguishable Mrs of 32 ± 1 and 31 ± 1 kDa [71]. Further 
processing of PK-treated VpAP by heat treatment (i.e. Step C) yielded 
a single species that was indistinguishable on SDS-PAGE (Lane 4, 
Figure 3) or by Co(II)-affinity resin binding behavior (Figure 5) from 
the major species observed prior to heat treatment; heat treatment 
served to denature fragments that had been cleaved upon PK 
treatment. In addition, following Step C, it was observed that the VpAP 
activity could be recovered from Co(II)-affinity resin with HEPES 
buffer, in the absence of imidazole, indicating that the C-terminal 
(His)6 region was no longer present following Steps B and C. The 
specific activity of 120 Units/mg for VpAP from Step C does not, in 
fact, indicate any enhancement of the activity per mole upon heat 
treatment, but reflects the removal of the cleaved N-terminal 
propeptide, about 60 % of which appeared to have denatured during 
PK-treatment and dialysis, and was removed by centrifugation, and 
the remainder of which was denatured by heat treatment. 
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Figure 3: Effects on SDS-PAGE analysis and N-terminal sequence of incubation with 
proteinase K and heat treatment on Co(II)-afinity resin-fractionated wild-type 
ΔspΔCVpAP*(His)6. Lane 1, Mr markers; Lane 2, Co(II)-afinity resin-fractionated 
ΔspΔCVpAP*(His)6; Lane 3, ΔspΔCVpAP*(His)6 fraction (Lane 2) incubated with 
proteinase K until maximum activity was reached; Lane 4, subsequent heat treatment 
of material from Lane 3. Band X (Lane 2) returned an N-terminal sequence EDKVWI; 
Bands Y and Z (Lanes 3 and 4, respectively) returned ASFVMP. 
 
 
Figure 5: Fractionation of VpAP at various stages of processing by Co(II)-affinity 
resin. Wild-type ΔspΔCVpAP*(His)6 obtained by Co(II)-affinity resin fractionation was 
re-applied to Co(II)-affinity resin without further treatment (Lanes 1 - 5), after 
incubation with proteinase K (Lanes 7 - 11), and after proteinase K and heat 
treatment (Lanes 13 - 17). Fractions were collected during application of the sample 
(“Flow-through”, Lanes 1, 7 and 13), during washing with HEPES buffer (Lanes 2, 3, 8 
and 14), and upon application of imidazole-containing buffer (Lanes 4, 5, 9 - 11 and 
15 - 17), and analyzed by SDS-PAGE. Mr markers are shown in Lanes 6 and 12. 
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Step D: The purpose of Step D was to separate any VpAP that had not 
had the C-terminal (His)6 removed during Step B and had yet 
remained undenatured during Steps B and C. SDS-PAGE analyses 
(Figure 5) indicated that no detectable amount of protein eluted from 
the Co(II)-affinity resin upon the application of imidazole. 
Expression and purification of VpAP:D99X variants 
10 L E. coli cultures, OD600 nm = 2.0 - 2.3, yielded 15 - 20 g wet 
weight of cells, which were discarded. From 1 to 2.5 mg of the D99-
substituted variants of VpAP were purified from the supernatants. 
Steady state activities towards LPNA were significantly lower than for 
wild-type VpAP: the activities of VpAP:D99M, VpAP:D99H and 
VpAP:D99A were 0.030 ± 0.002, 0.004 ± 0.001, and 1.5 × 10-4 to 3.5 
× 10-4 Units/mg, respectively. The purification of VpAP:D99M is 
summarized in Table 2. Apparent kinetic parameters of k′cat = 1.0 ± 
0.1 min-1, and K′m = 31 ± 7 μM were estimated from kinetic analysis 
of VpAP:D99M; meaningful values for K′m could not be obtained for the 
other variants due to the very low activities. 
Table 2: Purification of VpAP:D99M 
Purification step Volume 
(ml) 
Total protein 
(mg) 
Activity 
(Units) 
Specific activity 
(Units/mg) 
Supernatant clarification 10,000 120,000a N.D.b N.D.b 
Step A 20 3 N.D.b N.D.b 
Step Bc 20 N.D.b N.D.b N.D.b 
Step Ec 20 2.4 0.07 0.03 
Step Dd 60 2 0.06 0.03 
aVpAP was purified from the supernatant of bacterial cultures grown in LB medium, 
that originally contained about 12 g/L of a mixture of peptides, peptones and proteins. 
b“N.D.” signifies none detected. 
cStep B and Step E are alternative procedures; either Step B or Step E was carried 
out, not both. 
dStep D was carried out only on material from Step E, not from Step B. 
Step A processing of supernatant containing 
ΔspΔCVpAP:D99X*(His)6, where X = A, H or M, proceeded as for wild-
type VpAP, except that no activity towards LNPA was detectable at 
that stage. In addition, the apparent Mr of the bands that eluted from 
the Co(II)-affinity resin upon application of imidazole differed slightly 
from wild-type (SDS-PAGE of crude VpAP:D99A after Step A is shown 
as lane 4 of Figure 6 and crude VpAP:D99M is shown as Lane 1 of 
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Figure 7; compare with wild-type VpAP, lane 5, Figure 2). The 
differences between the non-reducing SDS-PAGE profiles of wild type 
VpAP and of the VpAP:D99X variants may be related to the cysteine 
content, just as the cysteine content may be responsible for the 
presence of multiple bands, some with Mr higher than the molecular 
species present, in the first place. In wild-type VpAP, the Cys223-
Cys227 disulfide bond is very stable, as attested to by the 
thermostability of VpAP. Asp99 is a key residue in a hydrogen bonding 
network that involves active site residues; indeed, it is of interest 
because of its possible structural and catalytic roles. 
 
Figure 6: Sensitivity of VpAP:D99A to incubation with proteinase K, monitored by 
SDS-PAGE analysis. Supernatant of E. coli culture expressing ΔspΔCVpAP:D99A*(His)6 
(Lane 2) was applied to Co(II)-affinity resin. Non-binding material flowed through the 
column in the absence of imidazole (Lane 3). ΔspΔCVpAP:D99A*(His)6 eluted with 
imidazole (Lanes 4 and 5) and was subsequently incubated with proteinase K for 10 - 
50 min (Lanes 6 - 10). 
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Figure 7: Autoprocessing of VpAP:D99M during extended dialysis monitored by SDS-
PAGE analysis. Lane 1, ΔspΔCVpAP:D99A*(His)6-containing fraction that eluted from 
Co(II)-affinity resin with imidazole; Lane 2, after 13 d dialysis against HEPES buffer at 
4 °C; Lane 3, Mr markers. 
The Cys223-Cys227 disulfide bond is also a key structural 
feature of the active site. It is perhaps possible that some active site 
local structure is preserved, even in the presence of SDS, in wild-type 
VpAP during SDS-PAGE; it is noteworthy that mass spectrometry has 
verified that purified, mature VpAP does not run on SDS-PAGE 
corresponding to its correct Mr [71]. The local structure may not be so 
preserved in VpAP:D99X variants, however; a hypersensitivity to PK 
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and heat treatment are consistent with lower structural stability. In 
that case, at least six bands may be expected on SDS-PAGE, three 
dimeric species with intermolecular disulfide bonds between the N-
terminal propeptide cysteine of one monomer and three monomeric 
species with a single disulfide; note that the suspected proximity of 
the N-terminal propeptide to the active site, suggested by the 
inhibitory effect on activity, would facilitate intramolecular disulfide 
bond formation between the N-terminal propeptide and either of 
Cys223 or Cys227 if the Cys223-Cys227 disulfide bond itself were not 
subject to additional stabilization. Further work that is outside the 
scope of the current study is clearly necessary to fully understand the 
behavior of VpAP polypeptide constructs on SDS-PAGE. However, there 
is available information on (i) the Cys content of mature and 
unprocessed VpAP constructs, (ii) the thermostability and stable 
disulfide bond in mature wild-type VpAP, (iii) the structural relationship 
between D99, the active site, and the disulfide bond, (iv) the much 
lower structural stability of D99 mutants and (v) the anomalous 
behavior on SDS-PAGE of purified, mature VpAP of mass-
spectrometry-verified Mr. These data are consistent with, and suggest 
a mechanism for, multiple bands on SDS-PAGE for unprocessed VpAP 
constructs, a single band for purified VpAP, and a different and more 
complex band profile for VpAP:D99X variants unprocessed polypeptide 
constructs than for wild-type. 
Upon treatment with PK (Step B), VpAP:D99A was rapidly 
degraded. After 10 min, bands at 28, 30 and 32 kDa were observable 
on SDS-PAGE, along with fragments of lower apparent Mr (lane 6, 
Figure 6). After 30 – 40 min, however, these bands had disappeared 
(lanes 8 and 9, Figure 6), and, after 50 min, no protein at all was 
observable on the gel (lane 10, Figure 6). 
The lengthy methods of either SDS-PAGE or measurement of 
very low levels of activity are, obviously, impractical for real-time 
determination of when to terminate Step B, and this procedure could 
not be reliably or reproducibly employed to process 
ΔspΔCVpAP:D99X*(His)6. Instead, the alternative procedure of 
extended dialysis without PK, Step E, was employed. VpAP:D99M 
displayed the same SDS-PAGE profile as VpAP:D99A, following Step A 
(lane 1, Figure 7), and a similar sensitivity to PK treatment. However, 
upon extended dialysis at 4 °C against HEPES buffer, the bands in the 
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range of apparent Mr = 30 − 40 kDa, and Mr ≈ 62 kDa, lost intensity 
and a band with apparent Mr ≈ 28 kDa emerged, corresponding to the 
31 ± 1 kDa species characterized by mass spectrometry, until, after 
13 d, only the band at Mr ≈ 28 kDa was observable (lane 2, Figure 7). 
The N-terminal amino acid sequence of this species was found to be 
TLASFVM, corresponding to the final six amino acids of the N-terminal 
propeptide, and the N-terminal methionine of mature VpAP; this 
confirmed that the N-terminus was autoprocessed during dialysis. Step 
D, a second application to Co(II)-affinity resin, was then carried out. 
SDS-PAGE analysis (Figure 8) clearly showed that VpAP:D99M isolated 
from Step E did not bind to the resin and that, therefore, the C-
terminal region had also been removed during Step E. Circular 
dichroism spectropolarimetery of D99M yielded a spectrum 
indistinguishable from that of the “32 kDa” form of wild-type 
recombinant, fully active enzyme (Figure 9). If Mr for VpAP:D99M were 
really 28 kDa, this could only correspond to the loss of a large C-
terminal α-helix, given the experimentally obtained N-terminal 
sequences, and the circular dichroism spectra would be expected to be 
significantly different. 
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Figure 8: Loss of (His)6 construct from VpAP:D99M. Lane 1, VpAP:D99M after 
extended dialysis; Lane 2, Flow-through from Co(II)-affinity resin during application of 
VpAP:D99M and washing with buffer; Lane 3, Eluate upon application of imidazole; 
Lane 4, Mr markers. Lane 1 corresponds to 1.2 μg protein and Lane 2 corresponds to 
0.3 μg protein (10 μl of the sample described in Table 2, in each case). 
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Figure 9: Circular dichroism spectra of recombinant wild-type VpAP (solid line) and 
VpAP:D99M (dashed line). 
Crystallization and crystallography of wild-type VpAP 
Wild type VpAP protein readily formed hexagonal crystals 
(Figure 10) with a space group of P6122. The structure was determined 
to a resolution of 1.95 Å (1 Å = 0.1 nm; PDB code 3F4H) and the 
crystallographic data collection and refinement statistics are given in 
Table 3. The protein fold was essentially identical to those structures 
already published. For comparison, the present structure, 3F4H, and 
an earlier structure, 1LOK [38], were superimposable (LSQMAN) with a 
root mean square deviation of 0.120 Å in Cα position. The inter-Zn 
distances were 3.40 Å (3F4H) and 3.45 Å (1LOK). The crystal structure 
also provided information on the C-terminus of the fully processed 
protein. The residues comprising the sequence MGSATG were all 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Protein Expression and Purification, Vol. 66, No. 1 (July 2009): pg. 91-101. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
23 
 
clearly identifiable from the electron density and, as with natively 
expressed VpAP, only the short C-terminal sequence DTPTPGNQ could 
not be inferred from X-ray diffraction. In addition, the pre-N-terminal 
residues ASFV were not clear from the X-ray diffraction data. The 
possible range of Mr for the crystallized recombinant VpAP is, then, 
31,388 to 32,640 D (not including Zn). 
 
Figure 10: Crystals of heterologously expressed VpAP. 
Table 3: Crystallographic data and refinement statistics for VpAP structure 
3F4H 
Data collection  
Resolution (Highest Resolution Shell) (Å) 50 - 1.95 (2.02 - 1.95) 
Total Reflections 79269 
Unique Reflections 23164 
Completeness (%) 95.5 (97.7) 
<I/(σI)> 11.6 (2.6) 
Cell Dimensions a = b = 108.4 Å, c = 93.5 Å; γ = 120° 
Space Group P6122 
Rmerge 0.094 (0.420) 
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Vm, Solvent Content 2.48 Å3 D-1, 50.4 % 
Monomers in Asymmetric Unit 1 
Refinement  
Number of Protein Atoms 2236 
Number of Water Molecules 150 
Number of Bound Ligands 8 
Number of Zn Atoms 2 
Number of Na Atoms 2 
Bav. Main Chain (Å2) 14.9 
Bav. Side Chain (Å2) 15.6 
Bav. Zn (Å2) 14.3 
Bav. Tris (Å2) 19.6 
Bav. Na (Å2) 11.1 
Bav. Water (Å2) 17.7 
Rcryst. / Rfree 0.191 / 0.229 
R.M.S.D. Bond Length / Angle 0.009 Å / 1.138° 
Ramachandran Plot  
Most Favored 88.4 % 
Additional Favored 11.2 % 
Generously Allowed 0.4 % (Met180) 
Discussion 
VpAP has been extensively studied, because of its high 
structural homology to many biomedically important 
metallohydrolases, and because of the actual and potential clinical 
utility of inhibitors of the enzyme [35, 36, 40]. In particular, the 
mechanism of action of the enzyme is seen as providing a prototypical 
template for the rational design of anti-cancer, anti-angiogenic and 
antibiotic chemotherapeutic agents. Despite much elegant work on the 
native wild-type enzyme, that has provided much insight into the 
catalytic mechanism, questions remain; even the roles of the distinct 
Zn(II) ions in the active site, once thought to be clear [60, 76, 97], 
are now somewhat controversial [39, 98]. The focus of recent 
structure-function research on VpAP, and on closely related enzymes, 
has been on site-directed variants [61-64, 98], as these may provide 
further insight into the structure-function relationships in VpAP. 
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A prerequisite to structure-function studies on site-directed 
variants of VpAP is a method by which these proteins can be 
expressed and purified. The challenges associated with heterologous 
expression and purification of VpAP are evident from earlier work, and 
have been particularly thoroughly addressed in a report by Bzymek, 
Holz and coworkers [71, 72]. Briefly, the problems include (i) the 
desirability of a mechanism by which VpAP is exported from the cell, to 
prevent inclusion body formation; (ii) the requirement for an N-
terminal propeptide for correct folding; (iii) the inhibitory nature of the 
N-terminal propeptide, which makes identification and quantitation of 
unprocessed VpAP* by activity very difficult; (iv) anomalous behavior 
of VpAP* on SDS-PAGE gels; (v) the need for aggressive treatment 
with proteases and heat to process VpAP* to VpAP; (vi) multiple 
lengthy and inefficient chromatographic separations. Despite these 
challenges, Bzymek et al. were able to design a protocol for isolation 
of heterologously expressed VpAP that yielded wild-type and some 
site-directed variant forms of VpAP. 
Despite the successes of the method of Bzymek, Holz and 
coworkers, two outstanding issues led us to revisit the expression and 
purification of VpAP from an E. coli expression system. The first was 
that we were unable to isolate some site-directed variants using this 
method. Where initial expression was low, the losses in terms of 
recoverable material during the traditional chromatographic steps were 
unacceptable. In addition, as our data clearly show, some variants 
were so sensitive to proteinase K treatment, and the procedure so 
difficult to control with variants exhibiting low specific activity, that 
incubation with proteinase K could not be reliably used to cleave the 
N-terminal propeptide. The second outstanding issue was that of final 
purity of the product. Many site-directed variants of interest in 
structure-function studies have very low activities compared to wild-
type VpAP. Reported activities of e.g. 0.004 % of that of wild-type 
have been reported [61]. Important mechanistic information is 
available from kinetic studies of variants with even very low activities; 
for instance, K′m informs on the ability of a kinetically compromised 
variant to form a Michealis complex with substrate. However, these 
studies rely on the level of contamination by other proteolytic enzymes 
being extremely low, much lower than can be determined by SDS-
PAGE. While heat treatment may be expected to denature most 
proteins other than VpAP, there is no analytical way to determine that 
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heat treatment does indeed destroy all contaminating proteases to a 
remaining level of ≪ 0.004 %. In addition, some VpAP site-directed 
variants are unstable toward heat treatment as well as toward 
proteinase K. 
The expression of VpAP as a construct with a (His)6 adduct 
facilitated a very rapid and effective first purification step. Three bands 
were evident on SDS-PAGE after this first step; two of the bands were 
shown to be due to ΔspΔCVpAP*(His)6, indicating anomalous behavior 
on SDS. Given (i) the known propensity of both unprocessed and 
processed VpAP to behave anomalously on SDS-PAGE, (ii) the 
requirement of imidazole for elution of the unprocessed material from 
the Co(II)-affinity resin, (iii) a constant ratio of the intensities of the 
three bands among fractions from the Co(II)-affinity column, and (iv) 
that a single product resulted from processing of the unprocessed 
material, it is likely that all three bands were due to 
ΔspΔCVpAP*(His)6. Earlier attempts to employ a “ΔC” construct, i.e. 
one lacking 43 amino acids of the C-terminal propeptide (“pET27b(+)-
43AAP”), resulted in a processed product with only 35 % of the activity 
of the native enzyme [71]. In contrast, processing of 
ΔspΔCVpAP*(His)6, in which the entire C-terminal propeptide was 
deleted, provided VpAP with activity as high as any reported and with 
K′m in the range of typically reported values. 
The use of a (His)6-containing construct allowed for rapid 
purification of VpAP but presented the concern that the (His)6 
construct may not be removed during processing. As VpAP is a 
transition ion-dependent enzyme, structure-function studies 
addressing the active site would be compromised by binding of metal 
ions to the (His)6 sequence. In particular, Co(II) is commonly used as 
a spectroscopically active substitute for the native Zn(II) but (His)6 
has a relatively high affinity for Co(II). An important final step, 
therefore, was the reapplication of fully processed VpAP to TALON 
Co(II)-affinity resin, and only fractions that did not bind, under the 
conditions that ΔspΔCVpAP*(His)6does bind, were retained. In 
practice, no SDS-PAGE-detectable material was actually observed in 
fractions collected upon subsequent application of imidazole, indicating 
highly efficient cleavage. The specific site of cleavage is unclear, but 
the crystal structure of wild-type VpAP indicated that it is somewhere 
in the short C-terminal sequence DTPTPGNQLE that immediately 
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precedes (His)6. The ready crystallization, and sub-2 Å X-ray 
diffraction of the crystals, suggests a highly pure and homogeneous 
final product. 
The use of the (His)6 construct was also applied to VpAP 
variants. One of the principal advantages was the rapid separation of 
fragile variants, such as the VpAP:D99X family, from other proteolytic 
enzymes. Studies with PK have shown these variants to be far less 
resistant than wild-type VpAP to proteolytic action, and the one-step 
Co(II)-affinity column isolation of ΔspΔCVpAP*:D99X(His)6 has 
replaced much lengthier and less effective hydrophobic interaction and 
anion exchange chromatographic steps that have been traditionally 
employed. Key to the use of ΔspΔCVpAP*:D99X(His)6, however, was 
the observation that solutions that had undergone exhaustive dialysis, 
followed by filtration, did not bind to Co(II)-affinity resin when 
reapplied. This observation suggested that ΔspΔCVpAP*:D99X(His)6 
was capable of autoprocessing. Along with a role for a neutral protease 
expressed by V. proteolyticus in processing VpAP*, autoprocessing by 
VpAP has also long been suspected. However, as crude preparations 
have not been free of other proteolytic activity, it has been difficult to 
confirm such a role. In the case of the ΔspΔCVpAP*:D99X(His)6 
variants, however, Co(II)-affinity resin chromatography provided a 
highly purified species, notwithstanding the anomalous behavior on 
SDS-PAGE. In addition to removal of the (His)6 adduct, exhaustive 
dialysis was shown by SDS-PAGE, and earlier mass spectrometry 
studies on wild-type VpAP, to have processed ΔspΔCVpAP*:D99X(His)6 
to a single species with Mr = 31 kDa. This indicated removal of the N-
terminal propeptide, and this was confirmed by N-terminal sequencing. 
It was confirmed by circular dichroism spectropolarimetry that 
extensive C-terminal processing did not occur, despite the apparent Mr 
of 28 kDa from SDS-PAGE. The 3 - 4 kDa C-terminal region that would 
have been lost from the 32 kDa protein to form a 28 kDa species 
would consist almost entirely of α-helix, and the circular dichroism 
spectrum would have differed significantly from that of wild-type in the 
200 - 240 nm region. 
In conclusion, we have developed protocols for purification of 
wild-type VpAP, and of protease-intolerant site-directed variants. The 
replacement of a C-terminal propeptide with a (His)6 adduct facilitates 
very rapid isolation of the expressed polypeptide from contaminating 
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proteolytic activity, from the supernatant of cultures of E. coli. Post-
translational processing of the purified polypeptide to the mature, 
functional enzyme can be effected by traditional exposure to heat or 
proteolytic activity or, for protease-intolerant variants, by an 
apparently autocatalytic mechanism. Isolation of a final product that is 
demonstrably devoid of the (His)6 construct is possible by a repeat 
application to Co(II)-affinity resin. This advance will facilitate the 
isolation and study of site-directed variants of VpAP with structure-
function relationship interest. 
Acknowledgments 
The authors would like to thank Wei Yong and Prof. Jung-Ja Kim, Department 
of Biochemistry, Medical College of Wisconsin, for invaluable assistance with 
crystallography. This work was supported by the National Institutes of Health 
(NIAID R01 AI056231 to B.B.). 
Abbreviations used 
ΔspVpAP*(His)6 heterologously expressed V. proteolyticus aminopeptidase 
polypeptide containing the N- and C-terminal propeptides, the mature 
enzyme region, and a C-terminal (His)6 construct, but lacking a 23 
amino acid N-terminal signal sequence 
ΔspΔCVpAP*(His)6 heterologously expressed V. proteolyticus 
aminopeptidase polypeptide containing the N-terminal propeptide, the 
mature enzyme region, and a C-terminal (His)6 construct, but lacking 
a 23 amino acid N-terminal signal sequence and the C-terminal 
propeptide 
HEPES N-(2-hydroxyethyl)-piperazine-N′-2-ethanesulfonic acid 
IPTG isopropyl β-D-1-thiogalactopyranoside 
LB Lysogeny broth (Luria-Bertani) 
LPNA L-leucine-p-nitroanilide 
mAP metalloaminopeptidase 
Mr relative molecular mass 
PK proteinase K from Tritirachium album 
PSMA prostate-specific membrane antigen 
VpAP Vibrio proteolyticus leucine aminopeptidase (32 kDa mature form) 
VpAP* Vibrio proteolyticus leucine aminopeptidase (54 kDa proenzyme) 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has 
been accepted for publication. As a service to our customers we are providing 
this early version of the manuscript. The manuscript will undergo copyediting, 
typesetting, and review of the resulting proof before it is published in its final 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Protein Expression and Purification, Vol. 66, No. 1 (July 2009): pg. 91-101. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
29 
 
citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply 
to the journal pertain. 
References 
1. Bradshaw RA. Protein translocation and turnover in eukaryotic cells. Trends 
Biochem Sci. 1989;14:276–279. 
2. Meinnel T, Mechulam Y, Blanquet S. Methionine as translation start signal: 
a review of the enzymes of the pathway in Escherichia coli. Biochimie. 
1993;75:1061–1075. 
3. Arfin SM, Bradshaw RA. Cotranslational processing and protein turnover in 
eukaryotic cells. Biochemistry. 1988;27:7979–7984. 
4. Bachmair A, Finley D, Varshavsky A. In vivo half-life of a protein is a 
function of its amino-terminal residue. Science. 1986;234:179–186. 
5. Arechaga G, Martinez JM, Prieto I, Ramirez MJ, Alba F, Ramirez M. Changes 
in membrane-bound leucine aminopeptidase activity during maturation 
and ageing of brain. Biochem Molec Biol Int. 1999;47:851–856. 
6. Babst R, Bongiorno L, Marini M, Marzano M, Spagnoli G, Roda LG, Urbani A. 
Age-induced increase of leucine enkephalin enzyme degradation in 
human plasma. Peptides. 1998;19:1155–1163. 
7. Martinez JM, Prieto I, Ramirez MJ, de Gasparo M, Hermoso F, Arias JM, 
Alba F, Ramirez M. Sex differences and age-related changes in human 
serum aminopeptidase A activity. Clinica Chim Acta. 1998;274:53–61. 
8. Mathe G. Bestatin, an aminopeptidase inhibitor with a multi-
pharmacological function. Biomed Parmacother. 1991;45:49–54. 
9. Ramirez M, Arechaga G, Sanchez B, Ozaita A, Lardelli P. Developmental 
and ageing changes in aminopeptidase activities in selected tissues of 
the rat. Experientia. 1993;49:300–303. 
10. Salminen A, Vihko V. Effects of age and prolonged running on proteolytic 
capacity in mouse cardiac and skeletal muscles. Acta Physiol Scand. 
1981;112:89–95. 
11. Betz P. Histological and enzyme histochemical parameters for the age 
estimation of human skin wounds. Int J Legal Med. 1994;107:60–68. 
12. Duranton B, Schleiffer R, Gosse F, Raul F. Preventive administration of 
ornithine alpha-ketoglutarate improves intestinal mucosal repair after 
transient ischemia in rats. Criti Care Med. 1998;26:120–125. 
13. Prager MD, Sabeh F, Baxter CR, Atiles L, Hartline B. Dipeptidyl peptidase 
IV and aminopeptidase in burn wound exudates: implications for 
wound healing. J Trauma. 1994;36:629–633. 
14. Spector GJ. The role of aminopeptidases in inflammatory and neoplastic 
tissues. Laryngoscope. 1976;86:1218–1240. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Protein Expression and Purification, Vol. 66, No. 1 (July 2009): pg. 91-101. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
30 
 
15. Spector GJ. Leucine and alanine aminopeptidase activities in 
experimentally induced intradermal granulomas and late stages of 
wound healing in the rat. Lab Invest. 1977;36:1–7. 
16. Blondin J, Taylor A. Measures of leucine aminopeptidase can be used to 
anticipate UV-induced age-related damage to lens proteins: ascorbate 
can delay this damage. Mech Ageing Dev. 1987;41:39–46. 
17. Fukui HN, Merola LO, Kinoshita JH. A possible cataractogenic factor in the 
Nakano mouse lens. Exp Eye Res. 1978;26:477–485. 
18. Sharma KK, Ortwerth BJ. Aminopeptidase III activity in normal and 
cataractous lenses. Curr Eye Res. 1986;5:373–380. 
19. Swanson AA, Davis RM, McDonald JK. Dipeptidyl peptidase III of human 
cataractous lenses. Partial purification. Curr Eye Res. 1984;3:287–
291. 
20. Swanson AA, Davis RM, Meinhardt NC, Kuck KD, Kuck JF., Jr Proteases in 
the Emory mouse cataract. Invest Opthalmol Vis Sci. 1985;26:1035–
1037. 
21. Taylor A, Daims M, Lee J, Surgenor T. Identification and quantification of 
leucine aminopeptidase in aged normal and cataractous human lenses 
and ability of bovine lens LAP to cleave bovine crystallins. Curr Eye 
Res. 1982;2:47–56. 
22. Velasco PT, Lukas TJ, Murthy SN, Duglas-Tabor Y, Garland DL, Lorand L. 
Hierarchy of lens proteins requiring protection against heat-induced 
precipitation by the alpha crystallin chaperone. Exp Eye Res. 
1997;65:497–505. 
23. Gutheil WG, Subramanyam M, Flentke GR, Sanford DG, Munoz E, Huber 
BT, Bachovchin WW. Human immunodeficiency virus 1 Tat binds to 
dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's 
immunosuppressive activity. Proc Natl Acad Sci USA. 1994;91:6594–
6598. 
24. Pulido-Cejudo G, Conway B, Proulx P, Brown R, Izaguirre CA. Bestatin-
mediated inhibition of leucine aminopeptidase may hinder HIV 
infection. Antivir Res. 1997;36:167–177. 
25. Schols D, Proost P, Struyf S, Wuyts A, De Meester I, Scharpe S, Van 
Damme J, De Clercq E. CD26-processed RANTES(3-68), but not intact 
RANTES, has potent anti-HIV-1 activity. Antivir Res. 1998;39:175–
187. 
26. Su SF, Amidon GL. Investigation into the intestinal metabolism of [D-
Ala1] peptide T amide: implication for oral drug delivery. Biochim 
Biophys Acta. 1995;1245:62–68. 
27. Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, 
Yamaoka Y, Miyake M. Aminopeptidase N is involved in cell motility 
and angiogenesis: its clinical significance in human colon cancer. 
Gastroenterol. 2002;122:376–386. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Protein Expression and Purification, Vol. 66, No. 1 (July 2009): pg. 91-101. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
31 
 
28. Lowther WT, Matthews BW. Structure and function of the methionine 
aminopeptidases. Biochim Biophys Acta. 2000;1477:157–167. 
29. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, 
Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. Aminopeptidase N is a 
receptor for tumor-homing peptides and a target for inhibiting 
angiogenesis. Cancer Res. 2000;60:722–727. 
30. Seli E, Senturk LM, Bahtiyar OM, Kayisli UA, Arici A. Expression of 
aminopeptidase N in human endometrium and regulation of its activity 
by estrogen. Fertil Steril. 2001;75:1172–1176. 
31. Zhang P, Nicholson DE, Bujnicki JM, Su X, Brendle JJ, Ferdig M, Kyle DE, 
Milhous WK, Chiang PK. Angiogenesis inhibitors specific for methionine 
aminopeptidase 2 as drugs for malaria and leishmaniasis. J Biomed 
Sci. 2002;9:34–40. 
32. Essler M, Ruoslahti E. Molecular specialization of breast vasculature: a 
breast-homing phage-displayed peptide binds to aminopeptidase P in 
breast vasculature. Proc Natl Acad Sci USA. 2002;99:2252–2257. 
33. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral 
membrane and secreted protein of activated lymphocytes. Scand J 
Immunol. 2001;54:249–264. 
34. Ishii K, Usui S, Sugimura Y, Yoshida S, Hioki T, Tatematsu M, Yamamoto 
H, Hirano K. Aminopeptidase N regulated by zinc in human prostate 
participates in tumor cell invasion. Int J Cancer. 2001;92:49–54. 
35. Holz RC, Bzymek KP, Swierczek SI. Co-catalytic metallopeptidases as 
pharmaceutical targets. Curr Opin Chem Biol. 2003;7:197–206. 
36. Bennett B. EPR of Co(II) as a structural and mechanistic probe of 
metalloprotein active sites: characterisation of an aminopeptidase. 
Curr Topics Biophys. 2002;26:49–57. 
37. Desmarais W, Bienvenue DL, Bzymek KP, Petsko GA, Ringe D, Holz RC. 
The high-resolution structures of the neutral and the low pH crystals of 
aminopeptidase from Aeromonas proteolytica. J Biol Inorg Chem. 
2006;11:398–408. 
38. Desmarais WT, Bienvenue DL, Bzymek KP, Holz RC, Petsko GA, Ringe D. 
The 1.20 A resolution crystal structure of the aminopeptidase from 
Aeromonas proteolytica complexed with Tris: a tale of buffer inhibition. 
Structure. 2002;10:1063–1072. 
39. Kumar A, Periyannan GR, Narayanan B, Kittell AW, Kim JJ, Bennett B. 
Experimental evidence for a metallohydrolase mechanism in which the 
nucleophile is not delivered by a metal ion: EPR spectrokinetic and 
structural studies of aminopeptidase from Vibrio proteolyticus. 
Biochem J. 2007;403:527–536. 
40. Stamper CC, Bienvenue DL, Bennett B, Ringe D, Petsko GA, Holz RC. 
Spectroscopic and X-ray crystallographic characterization of bestatin 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Protein Expression and Purification, Vol. 66, No. 1 (July 2009): pg. 91-101. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
32 
 
bound to the aminopeptidase from Aeromonas (Vibrio) proteolytica. 
Biochemistry. 2004;43:9620–9628. 
41. Stamper C, Bennett B, Edwards T, Holz RC, Ringe D, Petsko G. Inhibition 
of the aminopeptidase from Aeromonas proteolytica by L-
leucinephosphonic acid. Spectroscopic and crystallographic 
characterization of the transition state of peptide hydrolysis. 
Biochemistry. 2001;40:7035–7046. 
42. Burley SK, David PR, Sweet RM, Taylor A, Lipscomb WN. Structure 
determination and refinement of bovine lens leucine aminopeptidase 
and its complex with bestatin. J Mol Biol. 1992;224:113–140. 
43. Centres for Disease Control and Prevention. Aeromonas Wound Infections 
Associated with Outdoor Activities: California. Morb Mortal Wkly Rep. 
1990;39:334–335. 
44. Centres for Disease Control and Prevention. Outbreak of Vibrio 
parahaemolyticus infection associated with eating raw oysters and 
clams harvested from Long Island Sound: Connecticut, New Jersey and 
New York, 1998. Morb Mortal Wkly Rep. 1999;48:48–51. 
45. Liu S, Widom J, Kemp CW, Crews CM, Clardy J. Structure of human 
methionine aminopeptidase-2 complexes with fumagillin. Science. 
1998;282:1324–1327. 
46. Maras B, Greenblatt HM, Shoham G, Spungin-Bialik A, Blumberg S, Barra 
D. Aminopeptidase from Streptomyces griseus: primary structure and 
comparison with other zinc-containing aminopeptidases. Eur J 
Biochem. 1996;236:843. 
47. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-
angiogenic agent fumagillin covalently binds and inhibits the 
methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA. 
1997;94:6099–6103. 
48. Toma C, Honma Y. Cloning and genetic analysis of the Vibrio cholerae 
aminopeptidase gene. Infect Immun. 1996;64:4495–4500. 
49. Mahadevan D, Saldanha JW. The extracellular regions of PSMA and the 
transferrin receptor contain an aminopeptidase domain: implications 
for drug design. Protein Sci. 1999;8:2546–2549. 
50. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new 
antigenic marker in epithelial prostatic cells and serum of prostatic 
cancer patients. Anticancer Res. 1987;7:927–935. 
51. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A. 
Differential binding of drugs containing the NGR motif to CD13 
isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 
2002;62:867–874. 
52. Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, Liu JO. Molecular 
recognition of angiogenesis inhibitors fumagillin and ovalicin by 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Protein Expression and Purification, Vol. 66, No. 1 (July 2009): pg. 91-101. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
33 
 
methionine aminopeptidase 2. Proc Natl Acad Sci USA. 
1998;95:15183–15188. 
53. Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, Biemann K, Liu JO. 
Methionine aminopeptidase (type 2) is the common target for 
angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol. 
1997;4:461–471. 
54. Lowther WT, McMillen DA, Orville AM, Matthews BW. The anti-angiogenic 
agent fumagillin covalently modifies a conserved active-site histidine in 
the Escherichia coli methionine aminopeptidase. Proc Natl Acad Sci 
USA. 1998;95:12153–12157. 
55. Niimoto M, Hattori T. Prospective randomized controlled study on bestatin 
in resectable gastric cancer. Biomed Pharmacother. 1991;45:121–124. 
56. Sakuraya M, Tamura J, Itoh K, Kubota K, Naruse T. Aminopeptidase 
inhibitor ubenimex inhibits the growth of leukaemic cell lines and 
myeloma cells through its cytotoxicity. J Int Med Res. 2000;28:214–
221. 
57. Shibuya K, Chiba S, Hino M, Kitamura T, Miyagawa K, Takaku F, Miyazano 
K. Enhancing effect of ubenimex (bestatin) on proliferation and 
differentiation of hematopoietic progenitor cells, and the suppressive 
effect on proliferation of leukemic cell lines via peptidase regulation. 
Biomed Pharmacother. 1991;45:71–80. 
58. Taunton J. How to starve a tumor. Chem Biol. 1997;4:493–496. 
59. Vaughan MD, Sampson PB, Honek JF. Methionine in and out of proteins: 
targets for drug design. Curr Med Chem. 2002;9:385–409. 
60. DePaola C, Bennett B, Holz RC, Ringe D, Petsko G. L-Butaneboronic acid 
binding to Aeromonas proteolytica aminopeptidase: a case of arrested 
development. Biochemistry. 1999;38:9048–9053. 
61. Bzymek KP, Holz RC. The catalytic role of glutamate 151 in the leucine 
aminopeptidase from Aeromonas proteolytica. J Biol Chem. 
2004;279:31018–31025. 
62. Bzymek KP, Moulin A, Swierczek SI, Ringe D, Petsko GA, Bennett B, Holz 
RC. Kinetic, spectroscopic, and X-ray crystallographic characterization 
of the functional E151H aminopeptidase from Aeromonas proteolytica. 
Biochemistry. 2005;44:12030–12040. 
63. Bzymek KP, Swierczek SI, Bennett B, Holz RC. Spectroscopic and 
thermodynamic characterization of the E151D and E151A altered 
leucine aminopeptidases from Aeromonas proteolytica. Inorg Chem. 
2005;44:8574–8580. 
64. Davis RM, Bienvenue DL, Swierczek SI, Gilner D, Rajagopal L, Bennett B, 
Holz RC. Kinetic and spectroscopic characterization of the E134A- and 
E134D-altered dapE-encoded N-succinyl-L,L-diaminopimelic acid 
desuccinylase from Haemophilus influenzae. J Biol Inorg Chem. 
2006;11:206–216. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Protein Expression and Purification, Vol. 66, No. 1 (July 2009): pg. 91-101. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
34 
 
65. Merkel JR, Traganza ED. Possible symbiotic role of proteolytic and 
cellulolytic bacteria found in the digestive system of a marine isopod. 
Bact Proc. 1958:53–54. 
66. Prescott JM, Wilkes SH. Aeromonas aminopeptidase: purification and 
some general properties. Arch Biochem Biophys. 1966;117:328–336. 
67. Prescott JM, Wilkes SH. Aeromonas aminopeptidase. Methods Enzymol. 
1976;45:530–543. 
68. Schalk C, Remy JM, Chevrier B, Moras D, Tarnus C. Rapid purification of 
the Aeromonas proteolytica aminopeptidase: crystallization and 
preliminary X-ray data. Arch Biochem Biophys. 1992;294:91–97. 
69. Van Heeke G, Denslow S, Watkins JR, Wilson KJ, Wagner FW. Cloning and 
nucleotide sequence of the Vibrio proteolyticus aminopeptidase gene. 
Biochim Biophys Acta. 1992;1131:337–340. 
70. Guenet C, Lepage P, Harris BA. Isolation of the leucine aminopeptidase 
gene from Aeromonas proteolytica. Evidence for an enzyme precursor. 
J Biol Chem. 1992;267:8390–8395. 
71. Bzymek KP, D'Souza VM, Chen G, Campbell H, Mitchell A, Holz RC. 
Function of the signal peptide and N- and C-terminal propeptides in 
the leucine aminopeptidase from Aeromonas proteolytica. Prot Expr 
Purif. 2004;37:294–305. 
72. Zhang ZZ, Nirasawa S, Nakajima Y, Yoshida M, Hayashi K. Function of the 
N-terminal propeptide of an aminopeptidase from Vibrio proteolyticus. 
Biochem J. 2000;350(Pt 3):671–676.  
73. Prescott JM, Wilkes SH, Wagner FW, Wilson KJ. Aeromonas 
aminopeptidase. Improved isolation and some physical properties. J 
Biol Chem. 1971;246:1756–1764. 
74. Nirasawa S, Nakajima Y, Zhang ZZ, Yoshida M, Hayashi K. Intramolecular 
chaperone and inhibitor activities of a propeptide from a bacterial zinc 
aminopeptidase. Biochem J. 1999;341(Pt 1):25–31. 
75. Prescott JM, Wilkes SH. Aeromonas neutral protease. Methods Enzymol. 
1976;45:404–415. 
76. Bennett B, Holz RC. EPR studies on the mono- and dicobalt(II)-
substituted forms of the aminopeptidase from Aeromonas proteolytica. 
Insight into the catalytic mechanism of dinuclear hydrolases. J Am 
Chem Soc. 1997;119:1923–1933. 
77. Izawa N, Ishikawa S, Tanokura T, Ohta K, Hayashi K. Purification and 
characterization of Aeromonas caviae aminopeptidase possessing 
debittering activity. J Agric Food Chem. 1997;45:4897–4902. 
78. Tang B, Nirasawa S, Kitaoka M, Hayashi K. The role of the N-terminal 
propeptide of the pro-aminopeptidase processing protease: refolding, 
processing, and enzyme inhibition. Biochem Biophys Res Commun. 
2002;296:78–84. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Protein Expression and Purification, Vol. 66, No. 1 (July 2009): pg. 91-101. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
35 
 
79. Tang B, Nirasawa S, Kitaoka M, Hayashi K. In vitro stepwise 
autoprocessing of the proform of pro-aminopeptidase processing 
protease from Aeromonas caviae T-64. Biochim Biophys Acta. 
2002;1596:16–27. 
80. Baker JO, Wilkes SH, Bayliss ME, Prescott JM. Hydroxamates and aliphatic 
boronic acids: marker inhibitors for aminopeptidase. Biochemistry. 
1983;22:2098–2103. 
81. Tuppy H, Wiesbauer U, Wintesberger E. [Aminosäure-p-nitroanilide als 
substrate für aminopeptidäsen und andere proteolytische fermente]. 
Amino acid-p-nitroanilide as a substrate for aminopeptidases and other 
proteolytic enzymes. Hoppe Seylers Z Physiol Chem. 1962;329:278–
288. 
82. Marangoni AG. Enzyme Kinetics: A Modern Approach. John Wiley & Sons, 
Inc.; Hoboken, New Jersey: 2003. Characterization of enzyme activity; 
pp. 44–60. 
83. Edelhoch H. Spectroscopic determination of tryptophan and tyrosine in 
proteins. Biochemistry. 1967;6:1948–1954.  
84. Gill SC, von Hippel PH. Calculation of protein extinction coefficients from 
amino acid sequence data. Anal Biochem. 1989;182:319–326. 
85. Gill SC, von Hippel PH. Calculation of protein extinction coefficients from 
amino acid sequence data. Anal Biochem. 1990;189:283. Erratum. 
86. Rigaku. CrystalClear: An Integrated Program for the Collection and 
Processing of Area Detector Data. CrystalClear; Tokyo, Japan: 
19972002.  
87. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in 
oscillation mode. Methods Enzymol. 1997;276:307–326. 
88. Kumar A, Periyannan GR, Narayanan B, Kittell AW, Kim JJ, Bennett B. 
Experimental evidence for a metallohydrolase mechanism in which the 
nucleophile is not delivered by a metal ion: EPR spectrokinetic and 
structural studies of aminopeptidase from Vibrio proteolyticus. 
Biochem J. 2007;403:527–536. 
89. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read 
RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40:658–
674. 
90. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. 
Acta Crystallogr. 2004;60:2126–2132. 
91. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular 
structures by the maximum-likelihood method. Acta Crystallogr. 
1997;53:240–255. 
92. N. Collaborative Computational Project. The CCP4 suite: programs for 
protein crystallography. Acta Crystallogr. 1994;Sect. D 50:760–763. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Protein Expression and Purification, Vol. 66, No. 1 (July 2009): pg. 91-101. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
36 
 
93. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. Procheck: a 
program to check the stereochemical quality of protein structures. J 
Appl Crystallogr. 1993;26:283–291. 
94. Niino YS, Chakraborty S, Brown BJ, Massey V. A New Old Yellow Enzyme 
of Saccharomyces cerevisiae. J Biol Chem. 1995;270:1983–1991. 
95. Noel D, Nikaido K, Ames GF. A single amino acid substitution in a 
histidine-transport protein drastically alters its mobility in sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry. 
1979;18:4159–4165. 
96. Ustynyuk L, Bennett B, Edwards T, Holz RC. Inhibition of the 
aminopeptidase from Aeromonas proteolytica by aliphatic alcohols. 
Characterization of the hydrophobic substrate recognition site. 
Biochemistry. 1999;38:11433–11439. 
97. Prescott JM, Wagner FW, Holmquist B, Vallee BL. Spectral and kinetic 
studies of metal-substituted Aeromonas aminopeptidase: nonidentical, 
interacting metal-binding sites. Biochemistry. 1985;24:5350–5356. 
98. Ataie NJ, Hoang QQ, Zahniser MP, Tu Y, Milne A, Petsko GA, Ringe D. Zinc 
coordination geometry and ligand binding affinity: the structural and 
kinetic analysis of the second-shell serine 228 residue and the 
methionine 180 residue of the aminopeptidase from Vibrio 
proteolyticus. Biochemistry. 2008;47:7673–7683.  
 
 
